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 High-mobility group box 3 (HMGB3) is a chromatin-associated architectural protein that 
plays a role in regulating and supporting cellular DNA-dependent processes, such as optimizing 
DNA replication, transcription, and repair (1). Previous research has shown HMGB3 is often 
overexpressed in cancerous cells, which makes it a potential, novel target for therapeutic 
interventions that can help increase the efficacy of existing cancer therapies (2). This study 
aimed to develop a protocol that can successfully express eukaryotic HMGB3 using the bacterial 
system Escherichia coli (E. coli) so that functional HMGB3 can be prepared for high-throughput 
screenings in order to determine potential inhibitors for future drug studies.    
 Results revealed that the presence of rare codons within the DNA sequence of HMGB3 
were the biggest obstacles to successful expression. After codon optimization, HMGB3 DNA was 
inserted into a pET-28b vector containing His-tag and expressed alongside GroEL/ES chaperone 
using the E. coli strain BL21 (DE3) competent cells. Purification was achieved utilizing Ni-NTA 
affinity chromatography and Mono-Q 10/10 anion-exchange chromatography in succession. 




Chromatin is a complex made out of macromolecules that includes DNA and proteins, 
and it is located within the nucleus of eukaryotic cells. Its primary function is to package long 
DNA molecules into more compact structures, which helps protect the DNA sequence and 
regulate DNA dependent processes like the cell cycle. As a result, the structural organization of 
chromatin is essential for maintaining important gene expressions and cell identity. This 
structure is highly dynamic and is regulated by chromatin-associated architectural proteins (5). 
These architectural proteins are part of a central support system for cellular DNA-dependent 
processes and can regulate the efficiency of DNA repair, transcription, and replication (1). These 
functional aspects have made chromatin-associated proteins a target of interest for cancer 
research. Previous studies have shown that cancer-related somatic mutations have been found 
with high frequency for genes coding for chromatin-associated proteins, and the prognostic 
outcomes of several cancer types have also been linked to the expression levels of chromatin-
associated proteins. Of these proteins, the high mobility group box (HMGB) architectural 
protein family has been well studied in this regard and is of significant interest (1,5).  
HMGB proteins are an abundant and ubiquitous group of DNA binding proteins with a 
wide variety of cellular functions in the nucleus, cytoplasm, and extracellular matrix; but it is 
their vital role in regulating DNA damage responses and cell survival following treatment with 
chemotherapeutic agents, and their association with nucleotide base and strand repair, that 
makes HMGB proteins a valued target for cancer therapeutics (1, 6). The HMGB family consists 
of four proteins, with HMGB3 of particular interest due to it often being upregulated in cancer 
cells and having an important role in the developmental pathway of ovarian cancer (1). Thus, 
HMGB3 presents a potential, novel target that can significantly enhance current cancer 
treatments.  
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In order to identify potential HMGB3 inhibitors via high-throughput screening for drug 
studies, a bacterial expression system is required to produce functional, recombinant HMGB3 
proteins. Current protocols for expressing eukaryotic HMGB3 protein utilize mammalian cells, 
which can be costly for high-throughput studies and result in unwanted, post-translationally 
modified proteins (3,4). With no known protocols utilizing bacterial cells to express HMGB3, 
this study aimed to develop one using E. coli.  
 
Materials and Methods 
 
HMGB3 Sequencing and Codon Optimization 
 
Eukaryotic HMGB3 DNA was sequenced by GenScript and its rare codons were 
optimized for the E. coli bacterial expression system using the OptimumGene Codon 
Optimization software tool. GenScript synthesized a cloning plasmid containing the optimized 
HMGB3 construct, which would then be transferred to an expression vector.  
   
Construction of a His6-construct of HMGB3 in pET-28b 
 
 The DNA encoding human HMGB3 (GenBank accession number NM_005342) fused to 
an N-terminal hexahistidine tag was created using the following oligonucleotides: a) forward 
primer (5’-GGC AGC GGA GGG ATG GCT AAA GGT GAC CCC AAG AAA-3’) and b) reverse primer 
(5’-GAC CCA GAG CCA CC TTA TTC ATC CTC CTC CTC CTC-3’). Following ligation independent 
protocol, the PCR product and the linearized pET-28b plasmid was digested with T4 DNA 
Polymerase in order to create complementary sequence overhangs between the insert and 
vector for ligation. The HMGB3 digestion mix (20µl) contained 16µl of DNA, 2µl of buffer 2.1, 
and 1µl of dATP and T4 DNA Polymerase. The pET-28b digestion mix (50µl) contained 40µl of 
DNA, 5µl of buffer 2.1, and 2.5µl of dTTP and T4 DNA Polymerase. The digestion reaction was 
catalyzed by a thermocycler and the condition was set for 1 hour at 23°C, 20 minutes at 75°C, 
and storage at 4°C. Then 3µl of the digested HMGB3 PCR product and 1.5µl of the digested pET-
28b were mixed and let to anneal at room temperature for 10 minutes before transformation 
into DH5a E. coli cells. The sequence was verified at the Institute for Cell and Molecular Biology 
(ICMB) Sequencing Facility at the University of Texas at Austin. 
 
Expression and Purification of His-tagged HMGB3 
 
Expression of His-tagged HMGB3 
pET-28b-HMGB3 was co-transformed, along with pG-Tf2 (a kind gift from Dr. Gerhard 
Wagner), which carried the expression system for GroEL/ES chaperone, into the E.coli strain 
BL21 (DE3) competent cells. A single colony of freshly transformed cells was introduced to 10 
mL of LB media containing 30 µg/mL of kanamycin and 17 µg/mL chloramphenicol, and grown 
overnight at 37°C on a shaker (220 rpm). The culture was then diluted 100-fold into TB media 
containing 30 µg/mL of kanamycin and 17 µg/mL chloramphenicol, and incubated at 37°C (220 
rpm). The absorbance level was checked periodically until it reached an OD600 of 0.7. Protein 
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expression was then induced with 50µM isopropyl b-D-1-thiogalactopyranoside (IPTG) for 20 
hours at 25°C (220 rpm). The cells were harvested by centrifugation (8000 rpm for 12 min at 
4°C) in a 50 mL Falcon tube, flash frozen in liquid nitrogen, and stored at -80°C.  
 
Ni-NTA Affinity Chromatography 
 The bacterial pellet was thawed on ice and suspended in 300 mL of buffer A (20 mM Tris 
pH 8.0, 0.03% Brij-30, 0.1% (v/v) β-mercaptoethanol, 5 mM imidazole, 1mM benzamidine, 0.1 
mM PMSF, and 0.1 mM TPCK) containing 0.5 M NaCl, 20% glycerol and 0.2 mg/ml lysozyme at 4 
°C for 15 minutes, then 15 mL of 10% triton was added and mixed for another 15 min. The 
resuspended cells were divided into 100 mL fractions on ice and sonicated in a 4°C cold room 
for 10 min at 5 second intervals with a 50% cycle and 6 microtip limit. The lysate was cleared by 
centrifugation at 15,000 rpm for 30 minutes at 4°C and the supernatant was divided into 50 mL 
Falcon tubes. Each tube was introduced with 3.75 mL of Ni-NTA beads resuspended in buffer A, 
and gently rocked for 1 hour at 4°C. The solution was then transferred to a 100 mL 
chromatography column where the supernatant was eluted. The beads were then washed with 
300 mL buffer A containing 10 mM imidazole and 20% glycerol. His-tagged HMGB3 was then 
eluted with 30 mL buffer A containing 250 mM imidazole and 20% glycerol.  
 
Mono-Q 10/10 Anion-Exchange Chromatography 
 The eluted solution was applied to a Mono-Q 10/10 anion exchange column pre-
equilibrated with buffer B (20 mM Tris pH 8.0, (v/v) 0.03% Brij-30, (v/v) 0.1% β-
mercaptoethanol, 0.1 mM EDTA, 0.1 mM EGTA, and 10% glycerol). The column was developed 
over 15-17 column volumes of buffer B with a linear gradient of 0-0.5 M NaCl. The fractions 
associated with the chromatographic peak were collected and analyzed with SDS-PAGE Gel to 
confirm the presence and purity of HMGB3. For future experimentation, the fractions were 
pooled together and dialyzed overnight at 4°C with storage buffer C (25 mM HEPES pH 7.5, 50 





















HMGB3 Sequencing and Codon Optimization 
 
 The HMGB3 sequencing and codon optimization results from GenScript are represented 
by Fig. 1. With the OptimumGene Codon Optimization software tool, a total of 139 nucleotides 












601   
ATGGCTAAAG GTGACCCCAA GAAACCAAAG GGCAAGATGT CCGCTTATGC CTTCTTTGTG  
CAGACATGCA GAGAAGAACA TAAGAAGAAA AACCCAGAGG TCCCTGTCAA TTTTGCGGAA  
TTTTCCAAGA AGTGCTCTGA GAGGTGGAAG ACGATGTCCG GGAAAGAGAA ATCTAAATTT  
GATGAAATGG CAAAGGCAGA TAAAGTGCGC TATGATCGGG AAATGAAGGA TTATGGACCA  
GCTAAGGGAG GCAAGAAGAA GAAGGATCCT AATGCTCCCA AAAGGCCACC GTCTGGATTC  
TTCCTGTTCT GTTCAGAATT CCGCCCCAAG ATCAAATCCA CAAACCCCGG CATCTCTATT  
GGAGACGTGG CAAAAAAGCT GGGTGAGATG TGGAATAATT TAAATGACAG TGAAAAGCAG  
CCTTACATCA CTAAGGCGGC AAAGCTGAAG GAGAAGTATG AGAAGGATGT TGCTGACTAT  
AAGTCGAAAG GAAAGTTTGA TGGTGCAAAG GGTCCTGCTA AAGTTGCCCG GAAAAAGGTG  































ATGGCGAAGG GTGATCCGAA GAAACCGAAA GGCAAGATGA GCGCGTACGC GTTCTTTGTG  
CAGACCTGCC GTGAGGAACA CAAGAAAAAG AACCCGGAAG TGCCGGTTAA CTTCGCGGAG  
TTTAGCAAAA AGTGCAGCGA ACGTTGGAAG ACCATGAGCG GTAAAGAAAA GAGCAAATTC  
GATGAGATGG CGAAGGCGGA CAAAGTTCGT TACGATCGTG AGATGAAGGA CTATGGTCCG  
GCGAAAGGTG GCAAAAAGAA AAAGGACCCG AACGCGCCGA AACGTCCGCC GAGCGGCTTC  
TTTCTGTTCT GCAGCGAATT TCGTCCGAAG ATCAAAAGCA CCAACCCGGG TATCAGCATT  
GGCGATGTGG CGAAAAAGCT GGGCGAGATG TGGAACAACC TGAACGACAG CGAAAAGCAA  
CCGTATATTA CCAAAGCGGC GAAGCTGAAA GAAAAGTACG AGAAAGACGT TGCGGATTAT  
AAAAGCAAGG GCAAATTTGA TGGTGCGAAG GGTCCGGCGA AAGTGGCGCG TAAAAAGGTT  













Fig. 1. (A) Original DNA sequence of HMGB3. (B) Optimized DNA sequence of HMGB3 with altered 
nucleotides highlighted in yellow. (C) Amino acid sequence of optimized HMGB3 (GenBank accession 
number NM_005342). 
 
Purification of His-tagged HMGB3 
 
 The Mono-Q 10/10 anion-exchange chromatography result is represented by Fig. 2. The 
fractions associated with the largest UV peak were collected and run on an SDS-PAGE gel for 
confirmation as shown by Fig. 3. A concentrated band at around 25 kDa in each fraction, along 
with minimal interfering bands, confirmed the presence of relatively pure His-tagged HMGB3 
and indicated a successful expression with the E. coli bacterial system.  
 
 
      
        
Fig. 2. Eluted His-tagged HMGB3 from Ni-NTA chromatography was purified with Mono-Q 10/10 anion-
exchange chromatography. The red line marks the increasing concentration of NaCl while the blue line is 









Fig. 3. Samples from the purification process were resolved by SDS-PAGE: bacterial lysate (lane a), Ni-
NTA affinity chromatography eluted solution (lane b), Mono-Q 10/10 anion exchange chromatography 




 To summarize the findings of this study, His-tagged HMGB3 co-transformed with GroEL-
ES chaperone was efficiently expressed in Escherichia coli BL21 (DE3) competent cells using a 
pET-28b expression vector. After the expression was induced for 20 hours with 50 µM IPTG, the 
protein was isolated from the bacterial cell lysate using Ni-NTA affinity chromatography and 
further purified with Mono-Q 10/10 anion exchange chromatography (Fig. 2). Collecting the 
fractions associated with the strongest UV signal and running them on SDS-PAGE gel yielded a 
relatively pure, concentrated band at around 25 kDa, which is associated with His-tagged 
HMGB3 protein (Fig. 3). We found that optimizing HMGB3’s rare codons via GenScript’s 
OptimumGene Codon Optimization software tool prior to transformation proved to be the key 
to successfully expressing eukaryotic HMGB3 with a E. coli bacterial system (Fig.1).  
At the time of this research, there were no known protocol detailing the expression of 
eukaryotic HMGB3 using a bacterial system. We first investigated several vectors of interest by 
amplifying their DNA via PCR and checking for sequence stability. The expression vector pET-
32a was initially chosen because it contained a thioredoxin tag, which is a fusion tag that helps 
improve the solubility of the target protein and avoid aggregation of proteins. BL21 (DE3) E. 
coli. cells were initially used due to their high transformation and expression efficiency. 
However, the SDS-PAGE gel showed an unsuccessful expression. Even with a longer IPTG 
induced protein expression time, which was altered from 4 hours to 20 hours, the outcome did 
not change. We hypothesized that BL21 (DE3) E. coli cells had difficulty reading the eukaryotic 
HMGB3 insert due to the presence of rare codons, so Rosetta (DE3) competent cells were used 
in place of BL21 (DE3) E. coli cells because they are designed to enhance the expression of 
eukaryotic proteins containing codons rarely used in E. coli. When the SDS-PAGE gel once again 
showcased an unsuccessful expression, we analyzed HMGB3 DNA sequences and got its codons 





25 kDa  
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optimized using OptimumGene Codon Optimization software tool to be more compatible with 
E. coli. In addition, we selected to use the pET-28b vector containing only a His-tag, which we 
hypothesized would better express the optimized HMGB3 construct. Rosetta (DE3) was also 
replaced with BL21 (DE3) competent cells because the optimized HMGB3 sequence made 
Rosetta cells redundant, and BL21 cells are better suited to maximize protein expression. Lastly, 
GroEL/ES chaperone was co-transformed alongside optimized HMGB3 in order to promote 
optimal protein folding and prevent protein aggregation. Using these conditions, along with a 
20-hour IPTG induced protein expression, the SDS-PAGE gel confirmed a successful expression 
and yielded concentrated bands of relatively pure HMGB3 proteins.   
If given more time, the next step would be to assess the activity of the purified HMGB3 
protein with enzyme-substrate experiments in order to determine its viability for functional and 
structural studies. If HMGB3 is proven to be functionally active and structurally sound, then it 
would be used in high-throughput screenings in order to determine potential inhibitors for 
future drug studies. This research would have developed a reproducible protocol for preparing 
viable and pure recombinant HMGB3 via an E. coli expression system, and it would be 
significantly beneficial for studies interested in using HMGB3 as a novel target for cancer 
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